Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis

Abstract

Conflicting results have been widely reported on the use of Golgi protein 73 (GP73) as a serum biomarker for diagnosing hepatocellular carcinoma (HCC). This study evaluated the accuracy of GP73, alpha-fetoprotein (AFP), and GP73 + AFP for diagnosing HCC. The meta-analysis was performed on 11 studies that were selected by means of a comprehensive systematic literature review. Summary diagnostic accuracy, meta-regression analysis for heterogeneity and publication bias, and other statistical analyses were performed using Meta-Disc (version 1.4) and Stata (version 12.0). Pooled sensitivity, specificity, and diagnostic odds ratio were 0.77 (95% CI: 0.75–0.79), 0.91 (95% CI: 0.90–0.92), and 12.49 (95% CI: 4.91–31.79) for GP73; 0.62 (95% CI: 0.60–0.64), 0.84 (95% CI: 0.83–0.85), and 11.61 (95% CI: 8.02–16.81) for AFP; and 0.87 (95% CI: 0.85–0.89), 0.85 (95% CI: 0.84–0.86), and 30.63 (95% CI: 18.10–51.84) for GP73 + AFP. The area under the curve values were 0.86, 0.84, and 0.91 for GP73, AFP, and GP73 + AFP, respectively. These results indicate that for HCC diagnosis, the accuracy of GP73 was higher than that of AFP, and that GP73 + AFP exhibited significantly higher diagnostic accuracy than did GP73 or AFP alone.

miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker

“…Diagnosis of HCC is usually dependant on image techniques, blood indicators, and histopathology. 1,[6][7][8][9] These methods improve the detection of HCC to some degree, but the sensitivity and specificity for HCC screening remain unsatisfactory. At the same time, identification of the pathogenic mechanisms involved in HCC and development of useful prognostic biomarkers as well as novel targeted therapeutic strategies are the urgent clinical necessities, so we hope to find some new diagnostic biomarkers that can further improve the early detection of HCC in at-risk population.…”

Diagnostic value of long noncoding RNAs for hepatocellular carcinoma

“…DOR, another global index of diagnostic accuracy, [37] converts the strengths of sensitivity and specificity into a single indictor, and the larger the value of DOR is, the higher accuracy it indicates. [38] The overall pooled DOR of lncRNAs was 20 in this study, suggesting a moderate diagnostic accuracy.…”

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?

“…208 Golgi protein-73 (GOLPH2) is a transmembrane protein whose levels are elevated in patients with HBV and advanced fibrosis 209 and HCCs. 210,211 MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression may play a role in the diagnosis of HBV-related HCC, especially miRNA-21 and miRNA-122. 212 By identification of such biomarkers (Table 3), insights into the hepatocarcinogenesis pathway in HBV can be further studied, potentially identifying novel pathways and future HCC drug targets.…”